ABSTRACT

The present invention provides a pharmaceutical composition for treating or preventing anhedonia, including a selective δ opioid receptor agonist as an active ingredient, wherein preferably, the selective δ opioid receptor agonist further has κ opioid receptor antagonist action and μ opioid receptor antagonist action.